Citi analyst David Lebowitz has maintained their bullish stance on CRNX stock, giving a Buy rating today.
David Lebowitz has given his Buy rating due to a combination of factors that highlight Crinetics Pharmaceuticals’ promising future. The company has made significant clinical progress across its pipeline, with plans for its first commercial launch in 2025. The anticipated approval of paltusotine for acromegaly in September 2025 and the expected submission for EU approval in the first half of 2025 are key milestones.
Furthermore, Crinetics is preparing for the launch of paltusotine by targeting both switch patients and those newly diagnosed, aiming to transform the standard of care for acromegaly. The company is also advancing its pipeline with the initiation of several late-stage trials and new IND submissions, indicating a robust future development strategy. Despite increased operating expenses, Crinetics’ strong cash position is expected to fund operations into 2029, supporting its growth and development plans.
In another report released today, Piper Sandler also maintained a Buy rating on the stock with a $97.00 price target.